We offers novel blood-based products superior than standard of care. MamaCare is the 1st of its kind for monitoring breast cancer early recurrence. There are mre than 10 M BC women survivors in the US/Europe, representing ~ $3.4 B/y business opportunity. A $5M funding is needed to finance the 510(k) study for FDA clearance, commercialize our new test to regional hospitals together with an oncology and chronic disease test menu and seek an M&A.